You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
Efforts highlighted at last week's AACR meeting included new efforts to advance gene expression signatures, improve PD-L1 tests, and calculate MSI across tumor types.
Researchers at UC Santa Cruz have found patterns in RNA sequencing data that have led to possible treatments for cancers with no actionable mutations.
The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.
A new analysis of the study yielded mixed news for black women, confirming that they suffer worse outcomes, even with the same genetic test results and treatment.
In urothelial cancer, the presence of a gene signature stemming from stromal cells seemed to interfere with anti-PD-1 drug response in tumors with infiltrating T-cells.
An assessment concluded that Oncotype Dx has not demonstrated a significant enough impact on outcomes or cost effectiveness compared to current practice.